Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes
Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes
复制标题
DOI：
10.1007/s12185-022-03321-z
复制
发表时间：
2022-03-23
影响因子：
2.1
通讯作者：
Masaki，Yasufumi
中科院分区：
文献类型：
--
作者：
Yanagisawa，Hiroto;Kawabata，Hiroshi;Masaki，Yasufumi
已经开发了各种用于预测骨髓增生异常综合征（MDS）患者预后的系统。然而，性能状态（PS）和MDS的预后之间的关联需要进一步调查。为了客观评估PS对生存率的影响，我们检查了与PS相关的实验室检查结果，包括血清C反应蛋白（CRP）、白蛋白（ALB）和总胆固醇（CHOL）水平。患者（n= 123;男性86例，女性37例;中位年龄74岁）入选2010年至2020年期间在金泽医科大学医院诊断为MDS或骨髓增生异常/骨髓增生性肿瘤的患者，并根据受试者操作特征分析确定的临界值进行分组：CRP为0.44 mg/dL，ALB为4.0 g/dL，CHOL为120 mg/dL。中位随访期为17.6个月。Kaplan-Meier分析显示，高CRP、低ALB和低CHOL组的总生存期（OS）分别显著短于低CRP、高ALB和高CHOL组。多变量分析显示，血清CRP升高是一个独立的预后危险因素，与性别、骨髓原始细胞百分比和细胞遗传学无关。
Various systems for predicting the prognosis of patients with myelodysplastic syndromes (MDS) have been developed. However, associations between performance status (PS) and prognosis of MDS require further investigation. To objectively assess the impact of PS on survival, we examined laboratory findings associated with PS, including serum levels of C-reactive protein (CRP), albumin (ALB), and total cholesterol (CHOL). Patients (n= 123; male 86, female 37; median age 74 yrs.) diagnosed with MDS or myelodysplastic/myeloproliferative neoplasms at Kanazawa Medical University Hospital between 2010 and 2020 were enrolled and grouped by cutoff values determined by receiver operating characteristic analysis: 0.44 mg/dL for CRP, 4.0 g/dL for ALB, and 120 mg/dL for CHOL. The median follow-up period was 17.6 months. Kaplan–Meier analysis revealed that overall survival (OS) in the high CRP, low ALB, and low CHOL groups was significantly shorter than in the low CRP, high ALB, and high CHOL groups, respectively. Multivariable analysis revealed that elevated serum CRP was an independent prognostic risk factor independent of gender, bone marrow blast percentage, and cytogenetics.